A detailed history of China Universal Asset Management Co., Ltd. transactions in Ani Pharmaceuticals Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 4,045 shares of ANIP stock, worth $227,976. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,045
Previous 2,463 64.23%
Holding current value
$227,976
Previous $156,000 54.49%
% of portfolio
0.03%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$54.33 - $65.72 $85,950 - $103,969
1,582 Added 64.23%
4,045 $241,000
Q2 2024

Jul 19, 2024

SELL
$58.53 - $68.82 $91,892 - $108,047
-1,570 Reduced 38.93%
2,463 $156,000
Q1 2024

Apr 29, 2024

BUY
$54.2 - $69.69 $90,297 - $116,103
1,666 Added 70.38%
4,033 $279,000
Q4 2023

May 21, 2024

SELL
$48.72 - $65.43 $81,167 - $109,006
-1,666 Reduced 41.31%
2,367 $130,000
Q4 2023

Jan 23, 2024

BUY
$48.72 - $65.43 $90,326 - $121,307
1,854 Added 361.4%
2,367 $131,000
Q3 2023

May 21, 2024

BUY
$50.28 - $64.61 $12,469 - $16,023
248 Added 93.58%
513 $29,000
Q3 2023

Oct 30, 2023

BUY
$50.28 - $64.61 $12,469 - $16,023
248 Added 93.58%
513 $30,000
Q2 2023

May 21, 2024

BUY
$37.29 - $53.83 $1,081 - $1,561
29 Added 12.29%
265 $14,000
Q2 2023

Jul 27, 2023

BUY
$37.29 - $53.83 $1,081 - $1,561
29 Added 12.29%
265 $14,000
Q1 2023

May 21, 2024

BUY
$37.61 - $45.72 $2,181 - $2,651
58 Added 32.58%
236 $9,000
Q1 2023

Apr 27, 2023

BUY
$37.61 - $45.72 $2,181 - $2,651
58 Added 32.58%
236 $9,000
Q4 2022

May 21, 2024

SELL
$31.9 - $41.95 $122,974 - $161,717
-3,855 Reduced 95.59%
178 $7,000
Q4 2022

Jan 31, 2023

BUY
$31.9 - $41.95 $5,678 - $7,467
178 New
178 $7,000

Others Institutions Holding ANIP

About ANI PHARMACEUTICALS INC


  • Ticker ANIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 17,426,000
  • Market Cap $982M
  • Description
  • ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose produc...
More about ANIP
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.